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Since  2008,  the  World  Health  Organization  has provided  seed  grants  to 11  manufacturers  in low-  and
middle-income  countries  to  establish  or  improve  their  pandemic  inﬂuenza  vaccine  production  capacity.
To  facilitate  this  ambitious  project,  an  inﬂuenza  vaccine  technology  platform  (or  “hub”)  was  established  at
the  Netherlands  Vaccine  Institute  for  training  and  technology  transfer  to developing  countries.  During  its
ﬁrst  two  years  of  operation,  a robust  and  transferable  monovalent  pilot  process  for egg-based  inactivated
whole  virus  inﬂuenza  A vaccine  production  was  established  under  international  Good  Manufacturing
Practice  standards,  as  well  as  in-process  and  release  assays.  A  course  curriculum  was  designed,  including
a  two-volume  practical  handbook  on  production  and  quality  control.  Four  generic  hands-on  training
courses  were  successfully  realized  for over  40 employees  from  15  developing  country  manufacturers.
Planned  extensions  to  the curriculum  include  cell-culture  based  technology  for  viral  vaccine  production,
split  virion  inﬂuenza  production,  and  generic  adjuvant  formulation.  We  conclude  that  technology  transfer
through  the  hub  model  works  well,  signiﬁcantly  builds  vaccine  manufacturing  capacity  in developing
countries,  and  thereby  increases  global  and  equitable  access  to  vaccines  of  high  public  health  relevance.. Introduction
Until recently, international efforts to boost capacity in low- and
iddle-income countries along the vaccinology value chain have
een limited to quality control, regulatory support and clinical tri-
ls. The direct transfer of knowledge and technology for vaccine
anufacturing itself has received very little attention. This trend
irrors a decline in the number of domestic and regional vaccine
anufacturers in all parts of the world.
The (re)emergence of infectious diseases such as highly
athogenic avian inﬂuenza changed this picture. Governments saw
nvestment in health security and pandemic inﬂuenza prepared-
ess to be of increasing strategic importance. In several countries,
his has resulted in signiﬁcant national investment in manufactur-
ng capacity. At the global level, the threat of an inﬂuenza pandemic
as led to an acknowledged need for technical know-how and vac-
ine production capacity in developing countries.
In 2006, in response to the human-to-human transmission of
(H5N1), the World Health Organization (WHO) took steps to
nhance global access to inﬂuenza vaccine as part of its Global
andemic Inﬂuenza Action Plan [1]. This included a pioneering
roject to strengthen the capacity of developing countries to
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produce inﬂuenza vaccine. WHO  has to date provided seed grants
for this purpose to 11 manufacturers that belong to the Developing
Countries Vaccine Manufacturers Network (DCVMN), a voluntary,
public health driven network supported by international organiza-
tions and vaccinology resource institutions such as the Netherlands
Vaccine Institute (NVI) [2–4]. As the national vaccine agency of the
Ministry of Health, NVI is tasked with the supply of vaccines for
the Netherlands Immunization Programme, either through produc-
tion or procurement. Over the last decades, NVI has carried out
a number of technology transfer projects to developing country
manufacturers in various settings (Table 1) [3,5].
2. “Hub-based” transfer of technical know-how
In early 2007, to address numerous requests from countries
for support to their pandemic inﬂuenza vaccine production capac-
ity, WHO  developed the concept of a centralized technology and
training platform (a “hub”). The objective of the hub was to pool
public sector knowledge and expertise on a generic pilot pro-
cess for inﬂuenza vaccine production that could be transferred to
and easily scaled up in developing countries. Following a trans-
parent bidding process, WHO  selected NVI to fulﬁl this role, and
Open access under CC BY-NC-ND license.an International Technology Platform for Inﬂuenza Vaccines was
thus created in Bilthoven, the Netherlands [6]. A collaborative
agreement between WHO  and NVI was signed with the aim to
establish an egg-based production process for inactivated whole
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Table  1
Netherlands Vaccine Institute technology transfer projects.
Project Vaccine Approach Recipient Developing country
World Bank
(1990–1998)
Diphtheria-tetanus-
pertussis, measles, oral
polio
Turnkey SIBP, LIBP, KIMB, China
Haemophilus  inﬂuenza
type  b
(1999–now)
Haemophilus inﬂuenza type
b conjugate
Development and transfer
of  pilot process
Bio  Farma, SIIL, BE,
Glovax/SIBP
Indonesia
India
Republic of Korea/China
WHO  Sabin-IPV
(2008–now)
New  safer polio 1) Generic, hub
2)  Bilateral technology
transfer  agreements with
royalties
Potentially  several To be determined
WHO/NVI
(2007–now)
Egg-based  inactivated
inﬂuenza
1)  Generic, hub
2)  Bilateral technology
transfer  agreements
1)  15 developing country
manufacturers*
2)  Vacsera, IVAC
1) 12 countries
2)  Egypt, Viet Nam
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PIBP, Shanghai Institute of Biological Products; LIBP, Lanzhou Institute of Biological P
f  India Limited; BE, Biological E Limited; WHO, World Health Organization; IPV, i
nd  Medical Biologicals.
irion inﬂuenza vaccine and relevant documentation (standard
perating procedures, batch process records, validation methods,
nalytical methods and release criteria). The choice of technol-
gy was based on its simple and robust production process, and
herefore its feasibility for transfer to developing countries to pro-
uce pandemic inﬂuenza vaccine. In addition, whole virus vaccines
voke the broadest immune responses, are largely exempt from
ntellectual property hurdles and can be produced without using
icensed adjuvants [7]. This said, the ability to produce rapidly a
andemic vaccine invariably depends on the existence of annual
easonal inﬂuenza vaccine production; since split-virion vaccine
s by far the most widely used technology in seasonal inﬂuenza
rogrammes, NVI has added a process for split vaccine to its cur-
iculum.
. Establishment and validation of the basic process
The  process established at pilot scale (10,000 eggs) follows the
nternational quality and safety regulations of WHO  [8] and the
uropean Pharmacopoeia [9] (Fig. 1).
To determine robustness, we used one monovalent seasonal
train to set up and test a classical egg-based process in our facili-
ies. The main steps outlined in Fig. 1 can be summarized as follows.
he primary seed virus obtained from the National Institute for Bio-
ogical Standards and Control (NYMC X-175C reassortant derived
rom A/Uruguay/716/2007) was processed to working seed on spe-
iﬁc pathogen-free eggs before propagating the bulk virus at pilot
cale for 48–72 h in fertilized hen eggs at 35 ◦C. The virus-containing
uid was harvested semi-automatically and clariﬁed by centrifuga-
ion and depth ﬁltration. The virus was puriﬁed and concentrated
y sucrose gradient zonal ultracentrifugation and then inactivated
y ß-propriolactone, ﬁltrated using depth ﬁlters and further puri-
ed by subsequent ultraﬁltration/diaﬁltration. Finally, the product
as formulated and ﬁltrated at 0.22 m to obtain monovalent vac-
ine.
After producing 12 monovalent batches, the ﬁnal production
ettings were deﬁned and consistency runs performed. The aver-
ge recovery from zonal ultracentrifugation to monovalent vaccine
as 53% and the average yield 1.1 dose/egg. The sucrose den-
ity gradient puriﬁcation method – the international standard for
nﬂuenza virus puriﬁcation – resulted in the puriﬁcation proﬁle
hown in Fig. 2. The performance per process step and the impu-
ity proﬁle for the consistency runs are shown in Tables 2 and 3,
espectively. The ovalbumin, total protein and endotoxin con-
ent meet the speciﬁcations set by WHO  and the European
harmacopoeia.ts; KIMB, Kunming Institute of Medical and Biological Products; SIIL, Serum Institute
ated polio vaccine; NVI, Netherlands Vaccine Institute; IVAC, Institute of Vaccines
Comparison with other industrial processes is difﬁcult, as most
international manufacturers do not publish their process results.
We found one publication on density gradient yields [10] and
another comparing six European inﬂuenza vaccines for impurities
[11]. Our data on haemagglutinin antigen yield (Table 2) and impu-
rity proﬁle for ovalbumin and endotoxin (Table 3) ﬁtted well within
the ranges reported in these two studies.
4. Hands-on training courses
In  the preparatory phase, a suitable production training facil-
ity meeting international Good Manufacturing Practice standards
within NVI was  ﬁtted with all necessary equipment. Process steps
and test assays were set up and validated, and a two-volume
coursebook written. Extensive documentation on the entire pro-
cess was  generated including all standard operating procedures for
manufacturing and testing, and a Bill of Testing.
Participants for the training courses were selected in collabo-
ration with WHO. Of the 15 public and private entities trained to
date, 11 have represented manufacturers or regulatory agencies
supported by the WHO  inﬂuenza technology transfer project.
In  June 2009, the ﬁrst one-week interactive workshop was held
on quality assurance and GMP  aspects, including biosafety risk
analysis and management, for 13 participants. This was followed
in late 2009 and early 2010 by three courses of three weeks each
on inﬂuenza production and quality control for a total of 29 partic-
ipants. These courses addressed the production process in general,
as well as speciﬁc quality control and release assays of each indi-
vidual process such as 50% of the egg infectious dose (EID50) and
single radial immunodiffusion (SRID). Regulatory issues related
to inﬂuenza vaccines were covered, as well as the insights and
skills needed to work safely and securely. Each course included
a demonstration run at 10,000 egg pilot scale, and excursions to
external suppliers such as a private egg-breeding facility. Invited
international experts complemented the course faculty of NVI sci-
entists and researchers. Participants who successfully completed
the course were awarded a WHO  certiﬁcate.
In addition to the training courses, bilateral technology transfer
agreements have been signed with two WHO  grantees to ensure
further technical support to their vaccine manufacturing projects.
Additional staff from both institutions attended tailor-made train-
ing programmes at NVI in 2010. The surge of interest in these
courses from many countries and regions across the world, cre-
ated by the 2009 H1N1 pandemic, has led to a waiting list for the
next course which is scheduled for early 2011. The International
Technology Platform for Inﬂuenza Vaccines has a dedicated web
site as a communication tool for interested parties (www.itpiv.nl).
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Fig. 1. Egg-based pilot inﬂuenza vaccine production process.
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Fig. 2. Ovalbumin and haemagglutinin proﬁle in zonal sucrose gradient.
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Table  2
Performance per process step.
Process step Haemagglutinin recovery Bioburden removal Total protein removal Ovalbumin removal Sucrose removal
Unit (%) Log (%) (%) (%)
Clariﬁcation – Up to 1.3 – – –
Zonal  ultracentrifugation – Up to 1.2 92 99.993 –
Inactivation  89 Complete 26 – –
Ultraﬁltration/diaﬁltration 101 – 1 93.4 99.9
Formulation 98 – – – –
Sterile  ﬁltration 66 Complete – –
Average values obtained in three consistency runs. Bioburden reduction values were the maximum values achieved (removal depends on initial bioburden load of a batch).
Table  3
Impurity proﬁle of three consistency runs.
Min. Max. Spec [8;9]
Ovalbumin/HA ng/100 g HA 0.7 3.6 ≤2000
Total  protein/HA ug/100 g HA 225 245 ≤600
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sis of six European inﬂuenza vaccines. Eur J Clin Microbiol Infect Dis 1996
Feb;15(2):121–7.
[12]  Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S.
Intellectual property, technology transfer and manufacture of low-cost HPV
vaccines in India. Nat Biotechnol 2010;28(7):671–8.Endotoxin/HA IU/100 g HA 
Sucrose/HA mg/100 g HA 
A, haemagglutinin.
. Discussion
On the basis of evaluations held after our courses, and in
rder to serve a broader range of developing countries inter-
sted in inﬂuenza manufacturing, we are now extending the
nowledge base of our Centre. The basic process established for
onovalent seasonal strains will be used for pandemic strains,
llowing practical training in BSL2+ conditions. To validate the
rocesses developed and immunogenicity of the NVI vaccine,
linical batches of a candidate pandemic H5N1 strain (NIBRG23
/turkey/Turkey/1/2005) are being produced under GMP  for clini-
al studies in early 2011. We  will also extend the process to include
 step to serve parties that prefer split over whole virus pandemic
accine and those interested in seasonal vaccine production.
A  major challenge of the hub model is its sustainability. The
eed to secure NVI’s international role in building capacity for
ommon public goods such as those described here have led to
ther initiatives and innovative approaches that will be intro-
uced into the curriculum. For instance, we plan to develop and
ntroduce cell-culture based technology modules for viral vac-
ine production. Developing countries may  thereby enhance their
apacity to manufacture not only inﬂuenza, but also other vac-
ines of high public health relevance, such as rabies or rotavirus.
n addition, we serve as a training partner within the recently
aunched project for the technology transfer of an oil-in-water
djuvant for pandemic inﬂuenza vaccines in developing coun-
ries.
. Summary and concluding remarks
The ﬁrst years of operation have shown the International
echnology Platform for Inﬂuenza Vaccines to be a highly suc-
essful capacity-building tool. The egg-based pilot-scale process
stablished is robust, consistent and meets all international speci-
cations. The technology is easy to scale up and has proven suitable
or transfer to developing country manufacturers. The training and
echnology transfer objectives have been met, since participants at
he fully booked generic courses are successfully using the tech-
ology and know-how gained in their facilities, and two bilateral
onsultancy agreements for follow-up activities have been signed.
he generic hub approach to technology transfer can thus be seen as
omplementary to the bilateral partnerships for domestic inﬂuenza
accine production reported by the International Federation of0.09 4.19 ≤200
0.09 0.18 ≤0.4
Pharmaceutical Manufacturers & Associations, which usually focus
on ﬁll/ﬁnish activities.1
In conclusion, technology transfer from the public domain to
emerging developing country manufacturers and regulators will
increase global and equitable access to vaccines of high public
health relevance. The hub approach is thus meeting a critical inter-
national need, and may  be worth considering for other vaccines
needed in low- and middle-income countries [12].
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